Experienced in Small Lymphocytic Lymphoma (SLL)

Dr. Rayne H. Rouce

Pediatrics
301 University Blvd, 
Galveston, TX 
Accepting New Patients
14 Years of Experience
Experienced in Small Lymphocytic Lymphoma (SLL)
301 University Blvd, 
Galveston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rayne Rouce is a Pediatrics provider in Galveston, Texas. Dr. Rouce has been practicing medicine for over 14 years and is rated as an Experienced provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). Her top areas of expertise are Infantile Neutropenia, Classical Hodgkin Lymphoma, T-Cell Lymphoma, and Small Lymphocytic Lymphoma (SLL). Dr. Rouce is currently accepting new patients.

Her clinical research consists of co-authoring 66 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Small Lymphocytic Lymphoma (SLL).

Specialties
Pediatrics
Licenses
Pediatrics in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

301 University Blvd, Galveston, TX 77555

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2024
Intervention Type: Biological
Study Drugs: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
Study Phase: Phase 2
View 3 Less Clinical Trials

66 Total Publications

Clearing the hurdles for CAR-T cell treatment.
Clearing the hurdles for CAR-T cell treatment.
Journal: Nature reviews. Immunology
Published: September 22, 2025
Similar Doctors
Experienced in Small Lymphocytic Lymphoma (SLL)
Dr. Rafael A. Fonseca
Neonatology | Pediatrics
Experienced in Small Lymphocytic Lymphoma (SLL)
Dr. Rafael A. Fonseca
Neonatology | Pediatrics
301 University Blvd, Rt 0526, 
Galveston, TX 
 (0.1 miles away)
409-772-2815
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Rafael Fonseca is a Neonatologist and a Pediatrics provider in Galveston, Texas. Dr. Fonseca is rated as an Advanced provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). His top areas of expertise are Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Gastroschisis, and Atresia of Small Intestine. Dr. Fonseca is currently accepting new patients in some locations.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rouce's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile